Market Cap
$8.5B
PCVX
Vaxcyte, Inc.
$56.29 ▲ +0.44%
Prev close $56.05Market cap$8.5B
ConsensusStrong Buy
12-mo target$108.67 (+93.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)30 New Institutional Positions20 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on PCVX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$7.2B
Inst. Activity
30 buys / 20 sells
Insider Activity
$0.00 buy / $4.6M sell
Insider Net $
-$4.6M
SEC Reports
11
Press Releases
2
Congressional
1 trades
Price chart 30d -8.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Short Volume: PCVX — 64.5% short (0.4M / 0.5M)
Short: 351,326 | Exempt: 0 | TRF Vol: 544,567 | Short Ratio: 64.5% | Off-exchange volume (dark pool
Sep 9, 2026 Insider
Wassil Jim sold 1,334 shares
EVP, Chief Scientific Ofc, COO @ $59.52 ($79.4K)
Sep 8, 2026 Insider
PICKERING GRANT surrendered for taxes 17,056 shares
CHIEF EXECUTIVE OFFICER @ $60.36 ($1.0M)
Sep 8, 2026 Insider
Aug 6, 2026 SEC GUGGENHIME ANDREW surrendered for taxes 7,155 shares
PRESIDENT AND CFO @ $60.36 ($431.9K)
Two top executives at Vaxcyte — the CEO and CFO — sold a combined $395K in open-market stock over a one-week window, wit
CLUSTER — Impact 2/10
Jul 16, 2026 Congress
Jul 7, 2026 SEC Gilbert Cisneros buy
$1,001 - $15,000 — House
Two C-suite insiders at Vaxcyte (PCVX) sold shares worth $478K in the past week, but the amount is negligible relative t
CLUSTER — Impact 2/10
Insider selling cluster at Vaxcyte (PCVX): CEO Grant Pickering sold $363K and COO Jim Wassil sold $26K in open-market tr
CLUSTER — Impact 2/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Sep 25, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Aug 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Jul 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Jun 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% |
Price targets
Where 9 covering analysts think PCVX trades over the next 12 months.
$108.67 +93.0% upside Strong Buy
Current$56.30 Low$67.00 Median$110.00 High$163.00 9 analysts
$67.00$163.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 10 neutral · avg impact 3.3/10.Plus 2 press releases.
NEUTRALCLUSTER2/10
Two top executives at Vaxcyte — the CEO and CFO — sold a combined $395K in open-market stock over a
Aug 6, 2026
NEUTRALCLUSTER2/10
Two C-suite insiders at Vaxcyte (PCVX) sold shares worth $478K in the past week, but the amount is n
Jul 7, 2026
NEUTRALCLUSTER2/10
Insider selling cluster at Vaxcyte (PCVX): CEO Grant Pickering sold $363K and COO Jim Wassil sold $2
Jul 6, 2026
NEUTRAL1443/10
CEO Grant Pickering filed a Form 144 notice of intent to sell 24,237 shares of Vaxcyte (PCVX) with a
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
short_volume
Short Volume: PCVX — 64.5% short (0.4M / 0.5M)
Short: 351,326 | Exempt: 0 | TRF Vol: 544,567 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: PCVX — 64.6% short (0.3M / 0.5M)
Short: 335,345 | Exempt: 0 | TRF Vol: 519,029 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: PCVX — 66.7% short (0.4M / 0.7M)
Short: 435,455 | Exempt: 2 | TRF Vol: 653,228 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: PCVX — 67.7% short (0.5M / 0.8M)
Short: 535,496 | Exempt: 14,839 | TRF Vol: 790,784 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: PCVX — 66.8% short (0.5M / 0.7M)
Short: 460,919 | Exempt: 2,439 | TRF Vol: 689,774 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-2.14 | $-2.70–$-1.67 | -37.1% | +0.0% | 4↑ 0↓ | $0.0B | 7 |
| Next Q | $-2.05 | $-2.87–$-0.86 | -13.9% | +0.0% | 2↑ 1↓ | $0.0B | 7 |
| Current FY | $-8.20 | $-9.41–$-6.19 | -45.6% | +0.0% | 4↑ 0↓ | $0.0B | 7 |
| Next FY | $-7.22 | $-11.65–$-4.96 | 12.0% | +0.0% | 4↑ 0↓ | $0.1B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-2.139 | — |
| 7d ago | $-2.139 | — |
| 30d ago | $-2.139 | — |
| 60d ago | $-2.164 | +0.026 |
| 90d ago | $-2.164 | +0.026 |
Institutional ownership
Which big funds own PCVX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $7.2B total value (124,663,519 shares) as of 2026-Q2. Top holders: NOMURA, FMR, Jupiter. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 20,852,907 | $1.2B | 16.7% | ADD +26.4% |
| Jupiter Topco LLC | 17,965,847 | $1.0B | 14.4% | — |
| BlackRock, Inc. | 12,068,129 | $701.5M | 9.7% | — |
| RA CAPITAL MANAGEMENT, L.P. | 11,474,599 | $667.0M | 9.2% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 7,001,565 | $407.0M | 5.6% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,593,551 | $383.3M | 5.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,348,679 | $369.0M | 5.1% | — |
| STATE STREET CORP | 5,351,698 | $311.1M | 4.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,459,363 | $201.1M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 16,492,861 | 20,852,907 | +26.4% | $1.2B |
| WESTFIELD CAPITAL MANAGEMENT CO LP | TRIM | 3,646,138 | 2,472,428 | -32.2% | $143.7M |
| D. E. Shaw & Co., Inc. | TRIM | 2,865,318 | 1,901,872 | -33.6% | $110.6M |
| NORGES BANK | NEW | — | 1,245,805 | — | $72.4M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 375,772 | 1,194,754 | +217.9% | $69.4M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 350,000 | 880,000 | +151.4% | $51.2M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 355,854 | 782,184 | +119.8% | $45.5M |
| UBS Group AG | TRIM | 1,337,390 | 776,511 | -41.9% | $45.1M |
| Clearbridge Investments, LLC | DOUBLED | 128,377 | 751,999 | +485.8% | $43.7M |
| JENNISON ASSOCIATES LLC | TRIM | 1,698,011 | 476,216 | -72.0% | $27.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$4.6M — $0.00 bought, $4.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 1,334 | $59.52 | $79.4K |
| Sep 8, 2026 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | TAX W/H | 17,056 | $60.36 | $1.0M |
| Sep 8, 2026 | GUGGENHIME ANDREW | PRESIDENT AND CFO | TAX W/H | 7,155 | $60.36 | $431.9K |
| Sep 8, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | TAX W/H | 7,651 | $60.36 | $461.8K |
| Sep 8, 2026 | Cowan Elvia | SVP, Finance & CAO | TAX W/H | 1,327 | $60.36 | $80.1K |
| Sep 8, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | TAX W/H | 5,459 | $60.36 | $329.5K |
| Sep 4, 2026 | Jodar Luis | Chief Medical Officer | AWARD | 88,254 | — | — |
| Sep 4, 2026 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 1,381 | $61.16 | $84.5K |
| Sep 4, 2026 | Jodar Luis | Chief Medical Officer | AWARD | 52,632 | — | — |
| Sep 2, 2026 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | TAX W/H | 659 | $61.58 | $40.6K |
Congressional trades
PCVX trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | VAXCYTE INC | Sep 7, 2026(54d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PCVX.
Shares short
16,132,520
Settlement Sep 15, 2026
Change vs prior
+7.4%
Semi-monthly cycle
Days to cover
13.0
At avg daily volume
Of shares outstanding
≈10.8%
Estimate — not % of float
All PCVX filing & press-release reports (13)
- CLUSTER reportAug 6, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 6, 2026
- 144 reportJul 3, 2026
- 8-K reportJun 24, 2026
- CLUSTER reportJun 19, 2026
- PRESS-RELEASE reportJun 2, 2026
- 8-K reportMay 6, 2026
- DEFA14A reportApr 23, 2026
- CLUSTER reportApr 8, 2026
- PRESS-RELEASE reportMar 23, 2026
- 8-K reportFeb 24, 2026
- 8-K reportFeb 24, 2026